These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 30615206)

  • 21. Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes.
    Chen Z; Gao J; Li Z; Ma D; Wang Y; Cheng Q; Zhu J; Li Z
    Liver Int; 2024 Sep; 44(9):2477-2493. PubMed ID: 38924592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetic upregulation of TET2 is an independent poor prognostic factor for intrahepatic cholangiocarcinoma.
    Yamashita H; Tourna A; Akita M; Itoh T; Chokshi S; Ajiki T; Fukumoto T; Youngson NA; Zen Y
    Virchows Arch; 2022 May; 480(5):1077-1085. PubMed ID: 34905094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patterns of chromosomal copy-number alterations in intrahepatic cholangiocarcinoma.
    Dalmasso C; Carpentier W; Guettier C; Camilleri-Broët S; Borelli WV; Campos Dos Santos CR; Castaing D; Duclos-Vallée JC; Broët P
    BMC Cancer; 2015 Mar; 15():126. PubMed ID: 25879652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
    Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
    Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.
    Wintheiser G; Zemla T; Shi Q; Tran N; Prasai K; Tella SH; Mody K; Ahn D; Borad M; Bekaii-Saab T; Mahipal A
    JCO Precis Oncol; 2022 Jan; 6():e2100156. PubMed ID: 35005992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis.
    Sia D; Villanueva A; Friedman SL; Llovet JM
    Gastroenterology; 2017 Mar; 152(4):745-761. PubMed ID: 28043904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
    Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
    BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.
    Kinzler MN; Jeroch J; Klasen C; Himmelsbach V; Koch C; Finkelmeier F; Trojan J; Zeuzem S; Pession U; Reis H; Demes MC; Wild PJ; Walter D
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6391-6398. PubMed ID: 36757619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase-mutated intrahepatic cholangiocarcinomas.
    Delahousse J; Verlingue L; Broutin S; Legoupil C; Touat M; Doucet L; Ammari S; Lacroix L; Ducreux M; Scoazec JY; Malka D; Paci A; Hollebecque A
    Eur J Cancer; 2018 Feb; 90():83-91. PubMed ID: 29274619
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach.
    Ahn KS; O'Brien D; Kang YN; Mounajjed T; Kim YH; Kim TS; Kocher JA; Allotey LK; Borad MJ; Roberts LR; Kang KJ
    Hepatol Int; 2019 Jul; 13(4):490-500. PubMed ID: 31214875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
    Komuta M
    Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biology of IDH mutant cholangiocarcinoma.
    Wu MJ; Shi L; Merritt J; Zhu AX; Bardeesy N
    Hepatology; 2022 May; 75(5):1322-1337. PubMed ID: 35226770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
    Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
    Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome wide DNA copy number analysis in cholangiocarcinoma using high resolution molecular inversion probe single nucleotide polymorphism assay.
    Arnold A; Bahra M; Lenze D; Bradtmöller M; Guse K; Gehlhaar C; Bläker H; Heppner FL; Koch A
    Exp Mol Pathol; 2015 Oct; 99(2):344-53. PubMed ID: 26260902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular and radiopathologic spectrum between HCC and intrahepatic cholangiocarcinoma.
    Jeon Y; Kwon SM; Rhee H; Yoo JE; Chung T; Woo HG; Park YN
    Hepatology; 2023 Jan; 77(1):92-108. PubMed ID: 35124821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nestin may be a candidate marker for differential diagnosis between small duct type and large duct type intrahepatic cholangiocarcinomas.
    Sasaki M; Sato Y; Nakanuma Y
    Pathol Res Pract; 2024 Jan; 253():155061. PubMed ID: 38154357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDH mutations in liver cell plasticity and biliary cancer.
    Saha SK; Parachoniak CA; Bardeesy N
    Cell Cycle; 2014; 13(20):3176-82. PubMed ID: 25485496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients.
    Tang Z; Yang Y; Zhang Q; Liang T
    Clin Epigenetics; 2023 Jan; 15(1):13. PubMed ID: 36694230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma.
    Zhang X; Miao R; Liu T; Xiang X; Gu J; Jia Y; Li Z; Fu Y; He Y; Zhang Y; Zhang J; Qu K; Liu C
    Biomed Pharmacother; 2019 May; 113():108774. PubMed ID: 30889491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.
    Fujiwara H; Tateishi K; Kato H; Nakatsuka T; Yamamoto K; Tanaka Y; Ijichi H; Takahara N; Mizuno S; Kogure H; Matsubara S; Nakai Y; Koike K
    Cancer Sci; 2018 Nov; 109(11):3602-3610. PubMed ID: 30156013
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.